Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

GHK-Cu Side Effects Severity Distribution by Patient Phenotype

By
Published Updated Last reviewed
7 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Human evidence / Two small randomized trials of topical products: 13 completed one, 86 were evaluable in the other [2][3]
  • Adverse-event rates reported / None in either trial [2][3]
  • FDA concern for injectable GHK-Cu / Immunogenicity risk from aggregation and peptide-related impurities [4]
  • Approval status / No FDA-approved GHK-Cu drug; topical products are sold as cosmetics [5][6]
  • Injectable status / Not a cosmetic and not FDA-approved [6]

What the human trials measured

In one randomized trial, 13 patients completed a study of GHK-Cu skin care after CO2 laser resurfacing. Computer analysis and blinded evaluators found no significant difference in redness resolution, all patients improved in wrinkles and skin quality with no difference between groups, and a patient questionnaire favored GHK-Cu for overall skin quality (P=.04) [2].

A separate randomized evaluator-blinded trial tested a 0.4% tripeptide copper complex cream on venous stasis ulcers in 86 evaluable patients. The cream was no different from vehicle placebo for ulcer size, while silver sulfadiazine 1% reduced ulcer size [3].

Neither trial reports adverse-event rates, so there is no data to show who is more likely to react, or how severely. A 2026 review of the field says most randomized trials are small and use facial cosmetic creams [1].

What FDA says about injectable GHK-Cu

FDA lists "GHK-Cu (for injectable routes of administration)" in the nominated-but-withdrawn table on its page about bulk substances that may present significant safety risks. Its stated concern: "Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations." [4]

No FDA-approved drug contains GHK-Cu [5]. An injectable GHK-Cu product is not a cosmetic and is not FDA-approved [6].

Does a copper label answer the phenotype question?

Cupric chloride injection is an intravenous copper supplement used in nutrition, and its label does not cover GHK-Cu. The label contraindicates that product in patients with hypersensitivity to copper. It warns that copper given to patients with Wilson disease may increase hepatic accumulation of copper and aggravate the underlying hepatocellular degeneration, and that copper given to patients with cholestasis or cirrhosis may accumulate in the liver [7]. These are cautions for that intravenous product and do not establish GHK-Cu side-effect risk in any patient group.

Frequently asked questions

Is GHK-Cu FDA-approved?
No. No FDA-approved drug contains GHK-Cu. Topical copper peptide serums and creams are sold as cosmetics, which do not require FDA approval before sale, and an injectable GHK-Cu product is not a cosmetic and is not FDA-approved [5][6].
What did the human GHK-Cu trials find?
In one randomized trial, 13 patients completed a study of GHK-Cu skin care after CO2 laser resurfacing; objective measures found no significant difference in redness resolution, and a patient questionnaire favored GHK-Cu for overall skin quality (P=.04). A separate trial tested a 0.4% tripeptide copper complex cream on venous stasis ulcers in 86 evaluable patients; the cream was no different from vehicle placebo for ulcer size, while silver sulfadiazine 1% reduced ulcer size [2][3].
What is FDA's concern about injectable GHK-Cu?
FDA lists injectable GHK-Cu in the nominated-but-withdrawn table on its page about bulk substances that may present significant safety risks, citing potential immunogenicity from aggregation and peptide-related impurities, and limited human data [4].
Does the cupric chloride injection label apply to GHK-Cu?
No. Cupric chloride injection is an intravenous copper supplement used in nutrition, and its label does not cover GHK-Cu. The label describes copper hypersensitivity and liver-related cautions for that product [7].

References

  1. Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials
  2. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
  3. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
  5. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  6. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA
  7. U.S. National Library of Medicine, DailyMed. COPPER (cupric chloride) prescribing information. COPPER (cupric chloride) label
Evidence overview for GHK-Cu Side Effects Severity Distribution by Patient Phenotype